Media Articles Related to Guanfacine
Breast cancer treatments could increase risk of developing osteoporosis or hypertension
Source: Health News from Medical News Today [2014.02.28]
Older women who have overcome breast cancer are likely to struggle with heart disease, osteoporosis and hypertension further on in their lives. Whether these conditions occur or not is influenced by the treatment that patients received to fight cancer, their overall weight and their age. Breast cancer survivors therefore should watch their weight and get regular exercise so that they can enjoy a high quality of life. These findings, by lead author Nadia Obi of the University Medical Center Hamburg-Eppendorf, who collaborated with the group of Prof.
10 of 11 new gene signals are likely drug targets for hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2014.02.24]
A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.
Opsumit approved by SwissMedic for pulmonary arterial hypertension
Source: Hypertension News From Medical News Today [2014.02.17]
Actelion Ltd has announced that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland.Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III to reduce morbidity and the risk of mortality.
Air pollution increases risk for hypertension in pregnant women
Source: Hypertension News From Medical News Today [2014.02.14]
Breathing the air outside their homes may be just as toxic to pregnant women - if not more so - as breathing in cigarette smoke, increasing a mom-to-be's risk of developing deadly complications such as preeclampsia, according to findings from a new University of Florida study.
How the body regulates neuro-hormone has implications for hypertension, pain, stress, depression
Source: Anxiety / Stress News From Medical News Today [2014.02.12]
New research has revealed a previously unknown mechanism in the body which regulates a hormone that is crucial for motivation, stress responses and control of blood pressure, pain and appetite. The breakthrough could be used to design drugs to help fight health problems connected with these functions in the future.
Published Studies Related to Guanfacine
Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010.09.10]
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an extended-release (ER) tablet for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents (aged 6-17 years). In two large, randomized, double-blind, placebo-controlled trials of 8 and 9 weeks' duration, guanfacine ER (1-4 mg once daily) was effective in reducing the symptoms of ADHD (hyperactivity, impulsivity and inattention) in children and adolescents...
Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. [2010.09.01]
CONCLUSIONS: In this population of children aged 6-12 years with ADHD and the presence of oppositional symptoms, significant reductions in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores were observed with guanfacine XR treatment compared with placebo. Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs. The findings of this study support the efficacy of guanfacine XR in the treatment of children with ADHD and the presence of oppositional symptoms. Clinical Trial Registration Number: NCT00367835.
Guanfacine extended-release: in attention deficit hyperactivity disorder. 
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an
extended-release (ER) tablet for the treatment of attention deficit hyperactivity
disorder (ADHD) in children and adolescents (aged 6-17 years). In two large,
randomized, double-blind, placebo-controlled trials of 8 and 9 weeks' duration,
guanfacine ER (1-4 mg once daily) was effective in reducing the symptoms of ADHD
(hyperactivity, impulsivity and inattention) in children and adolescents...
Effects of extended-release guanfacine on ADHD symptoms and sedation-related
adverse events in children with ADHD. 
CONCLUSION: These results suggest that acclimation to GXR may minimize the risk
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. [2009.02]
CONCLUSIONS:: Guanfacine extended-release was effective in reducing symptoms of ADHD. Adverse events were mild to moderate, did not interfere with improvements in attention, and rarely led to discontinuation.
Clinical Trials Related to Guanfacine
Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia [Active, not recruiting]
Our overall aim is to determine if the administration of guanfacine in combination with
aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than
any of those medications alone in treating some of the cognitive impairment in
Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia [Recruiting]
This study seeks to determine, using special sleep tests (polysomnography and actigraphy) if
guanfacine extended release is able to improve nighttime sleep in children with ADHD -
associated insomnia while improving daytime ADHD symptoms. Male and female children with
diagnosed or suspected ADHD with sleep problems (difficulty falling asleep, difficulty
staying asleep, or less than expected hours of sleep) will be recruited. After obtaining
informed consent and assent (when appropriate) and after discontinuation of excluded
medications, children will have evaluations of his or her sleep and evaluations confirming
the ADHD diagnosis. Children who successfully pass screening will be enrolled into the
double-blind, placebo-controlled, randomized investigation with 50% of participants
receiving guanfacine extended release and 50% of participants receiving matching placebo.
Using a flexible-dose optimization design based on ADHD symptom improvement and medication
tolerability, the dose will be adjusted between 1 to 4 mg over the course of four weeks. At
the end of medication adjustment (week 4 or 5), ADHD questionnaires, sleep questionnaires,
and sleep tests will be repeated and analyzed. The medication will be weaned over the course
of the following 3-10 days.
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects [Recruiting]
This proposal aims to determine whether low does of the alpha-2A-adrenoceptor agonist
guanfacine can improve deficits in prefrontally-mediated cognitive functions in healthy
Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD) [Recruiting]
All subjects with the study will be children (age 6-12) with Attention Deficit Hyperactivity
Disorder (ADHD). After baseline assessment confirms the presence of ADHD, children will
have an Event related potential (ERP) (a type of electroencephalogram [EEG]) study. After
the baseline EEG, children will be randomized to either placebo or GXR for a 4-week,
parallel groups trial. During this trial, dosing will be flexibly adjusted according to
patient response or presence of side effects. The dosage will range from 1-4 mg. At the
end of the four week trial, a follow up ERP study will be obtained.
Guanfacine in Children With Tic Disorders [Recruiting]
The goal of this pilot study is to obtain preliminary information on the tolerability and
efficacy of extended release guanfacine (trade name Intuniv) in children with Tourette
Disorder (TD, also called Tourette syndrome).
Reports of Suspected Guanfacine Side Effects
Confusional State (3),
Coordination Abnormal (3),
Swelling Face (3),
Swollen Tongue (3),
Blood Pressure Decreased (3),
Complex Partial Seizures (3),
LIP Swelling (1), more >>